Mouse monoclonal antibodies against the idiotype of human B cell non-Hodgkin lymphomas: production, characterization and use to monitor the progress of diseaseRANKIN, E. M; HEKMAN, A.European journal of immunology. 1984, Vol 14, Num 12, pp 1119-1126, issn 0014-2980Article

Hypersensitivity reaction to epirubicinCASSIDY, J; RANKIN, E. M.Medical oncology and tumor pharmacotherapy. 1989, Vol 6, Num 4, pp 297-298, issn 0736-0118Article

Metastatic vipoma arising from colonic primary tumourBRADLEY, C; HADDOCK, G; PICKARD, R. G et al.European journal of surgical oncology. 1989, Vol 15, Num 4, pp 386-389, issn 0748-7983, 4 p.Article

Phase I and pharmacokinetic study of flavone acetic acidKERR, D. J; KAYE, S. B; CLAVEL, M et al.Cancer research (Baltimore). 1987, Vol 47, Num 24, pp 6776-6781, issn 0008-5472, 1Article

Dynamic studies of lymphocytes labelled with indium-111 during and after treatment with monoclonal anti-idiotype antibody in advanced B cell lymphomaRANKIN, E. M; HEKMAN, A; HARDEMAN, M. R et al.British medical journal (1857). 1984, Vol 289, Num 6452, pp 1097-1100, issn 0007-1447Article

A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancerRANKIN, E. M; MILL, L; HABESHAW, T et al.British journal of cancer. 1992, Vol 65, Num 2, pp 275-281, issn 0007-0920Article

A pilot study of quinidine and epirubicin in the treatment of advanced breast cancerJONES, R. D; KERR, D. J; HARNETT, A. N et al.British journal of cancer. 1990, Vol 62, Num 1, pp 133-135, issn 0007-0920, 3 p.Article

Phase I clinical and pharmacokinetic study of LY 195448CASSIDY, J; LEWIS, C; ADAMS, L et al.Cancer chemotherapy and pharmacology. 1989, Vol 24, Num 4, pp 233-237, issn 0344-5704Article

A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervixCOLEMAN, R. E; HARPER, P. G; WILTSHAW, E et al.Cancer chemotherapy and pharmacology. 1986, Vol 18, Num 3, pp 280-283, issn 0344-5704Article

Observations on the toxicity of the combination of gentamicin and mezlocillin in the treatment of patients with acute leukaemiaRANKIN, E. M; JONES, D. M; LAWSTON, F. G et al.Journal of antimicrobial chemotherapy (Print). 1984, Vol 14, Num 4, pp 411-421, issn 0305-7453Article

Catheter-related complications in 52 patients treated with continuous infusion of low dose recombinant interleukin-2 via an implanted central venous catheterVLASVELD, L. T; RODENHUIS, S; RUTGERS, E. J. T et al.European journal of surgical oncology. 1994, Vol 20, Num 2, pp 122-129, issn 0748-7983Article

Autonomic neuropathy following treatment with flavone acetic acidLEWIS, C. R; JARDINE, A; RANKIN, E. M et al.European journal of cancer & clinical oncology. 1989, Vol 25, Num 3, pp 573-574, issn 0277-5379Article

Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonistCASSIDY, J; RAINA, V; LEWIS, C et al.British journal of cancer. 1988, Vol 58, Num 5, pp 651-653, issn 0007-0920Article

A mathematical model of the development of drug resistance to cancer chemotherapyBIRKHEAD, B. G; RANKIN, E. M; GALLIVAN, S et al.European journal of cancer & clinical oncology. 1987, Vol 23, Num 9, pp 1421-1427, issn 0277-5379Article

The luminescence immunoassay S-100 : a sensitive test to measure circulating S-100b : its prognostic value in malignant melanomaBONFRER, J. M. G; KORSE, C. M; NIEWEG, O. E et al.British journal of cancer. 1998, Vol 77, Num 12, pp 2210-2214, issn 0007-0920Article

Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19VLASVELD, L. T; HEKMAN, A; VYTH-DREESE, F. A et al.Cancer immunology and immunotherapy. 1995, Vol 40, Num 1, pp 37-47, issn 0340-7004Article

Recombinant interleukin-2 in cancer: basic and clinical aspectsVLASVELD, L. T; RANKIN, E. M.Cancer treatment reviews. 1994, Vol 20, Num 3, pp 275-311, issn 0305-7372Article

A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. I: Clinical aspectsVLASVELD, L. T; RANKIN, E. M; HEKMAN, A et al.British journal of cancer. 1992, Vol 65, Num 5, pp 744-750, issn 0007-0920Article

Transcatheter embolisation to control severe bleeding in fungating breast cancerRANKIN, E. M; RUBENS, R. D; REIDY, J. F et al.European journal of surgical oncology. 1988, Vol 14, Num 1, pp 27-32, issn 0748-7983Article

First-into-man phase I and pharmacokinetic study of XR5944.14, a novel agent with a unique mechanism of actionVERBORG, W; THOMAS, H; BISSETT, D et al.British journal of cancer. 2007, Vol 97, Num 7, pp 844-850, issn 0007-0920, 7 p.Article

Clinical and endoscopic features of melanoma metastases in the upper GI tractTAAL, B. G; WESTERMAN, H; BOOT, H et al.Gastrointestinal endoscopy. 1999, Vol 50, Num 2, pp 261-263, issn 0016-5107Article

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancerKAYE, S. B; PAUL, J; RANKIN, E. M et al.Journal of clinical oncology. 1996, Vol 14, Num 7, pp 2113-2119, issn 0732-183XArticle

Phase II study of intermittent continuous infusion of low-dose recombinant interleukin-2 in advanced melanoma and renal cell cancerVLASVELD, L. T; HORENBLAS, S; HEKMAN, A et al.Annals of oncology. 1994, Vol 5, Num 2, pp 179-181, issn 0923-7534Article

Possible role for cytotoxic lymphocytes in the pathogenesis of acute interstitial nephritis after recombinant interleukin-2 treatment for renal cell cancerVLASVELD, L. T; VAN DE WIEL-VAN KEMANADE, E; DE BOER, A. J et al.Cancer immunology and immunotherapy. 1993, Vol 36, Num 3, pp 210-213, issn 0340-7004Article

Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumoursDERCKSEN, M. W; HOEKMAN, K; TEN BOKKEL HUININK, W. W et al.British journal of cancer. 1993, Vol 68, Num 5, pp 996-1003, issn 0007-0920Article